Dr. Michael J Redmond, M.D. Dermatology - Procedural Dermatology Medicare: Accepting Medicare Assignments Practice Location: 128 Medical Park Rd Ste 201, Mooresville, NC 28117 Phone: 704-235-1827 Fax: 734-464-9515 |
Bishr Al Dabagh, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 118 Gateway Blvd Ste A, Mooresville, NC 28117 Phone: 704-230-1302 |
Steven Frederick Wolfe, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 114 Gateway Blvd, Unit D, Mooresville, NC 28117 Phone: 704-663-2085 |
Dr. Joel H Sugarman, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 140 Leaning Oak Drive, Ste 101, Mooresville, NC 28117 Phone: 704-658-9730 Fax: 704-658-1457 |
Dr. Naomi Soroosh Simon, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 128 Medical Park Rd, Suite 201, Mooresville, NC 28117 Phone: 704-235-1827 Fax: 704-235-1823 |
Blake Sanders, DO Dermatology Medicare: Accepting Medicare Assignments Practice Location: 170 Medical Park Rd Ste 203, Mooresville, NC 28117 Phone: 980-550-2400 Fax: 980-550-2424 |
News Archive
Belmont Village Senior Living will officially open its 20th community in August 2011 at 3680 N. Moorpark Road in Thousand Oaks. The company has opened an on-site Information Center to provide details about leasing and the care and amenities that will be available for residents.
The National Children's Health Survey published results from a 2007 telephone survey in Pediatrics today in which 78,000 households in the US were asked if their child (ages 2-17) was known to "currently have autism, Asperger's Disorder, pervasive development disorder, or other autism spectrum disorder." The survey showed that 1% of children (one in 100) now have the disorder. Previous estimates from the CDC had reported a prevalence rate of one in 150.
Eli Lilly and Company today announced the sale of its Tippecanoe Laboratories manufacturing facility to Evonik Industries AG, one of the world's largest chemical companies.
Healthper, Inc., a social game-based health engagement and achievement platform, announced today the launch of a mobile application for Apple mobile devices.
The removal of Tysabri from the market soon after its introduction is expected to increase scrutiny of other similar drugs in development for multiple sclerosis (MS), says ECRI, a leading, independent health services research agency.
› Verified 3 days ago